Literature DB >> 26075427

A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma.

Steven C Kao1,2,3, Michael Fulham3,4, Kirby Wong4, Wendy Cooper3,4,5, Himanshu Brahmbhatt6, Jennifer MacDiarmid6, Scott Pattison6, Jin Og Sagong1, Yennie Huynh2, Felicity Leslie2, Nick Pavlakis3,7, Stephen Clarke3,7, Michael Boyer1,3, Glen Reid2,3, Nico van Zandwijk2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26075427     DOI： 10.1164/rccm.201503-0461LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  26 in total

Review 1.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

2.  MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Authors:  L Venturutti; R I Cordo Russo; M A Rivas; M F Mercogliano; F Izzo; R H Oakley; M G Pereyra; M De Martino; C J Proietti; P Yankilevich; J C Roa; P Guzmán; E Cortese; D H Allemand; T H Huang; E H Charreau; J A Cidlowski; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

Review 3.  Exploiting microRNAs As Cancer Therapeutics.

Authors:  Tamsin Robb; Glen Reid; Cherie Blenkiron
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

4.  Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.

Authors:  Jing-Hung Wang; Alexis V Forterre; Jinjing Zhao; Daniel O Frimannsson; Alain Delcayre; Travis J Antes; Bradley Efron; Stefanie S Jeffrey; Mark D Pegram; A C Matin
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

5.  Extracellular Vesicle-Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity.

Authors:  Alexis V Forterre; Jing-Hung Wang; Alain Delcayre; Kyuri Kim; Carol Green; Mark D Pegram; Stefanie S Jeffrey; A C Matin
Journal:  Mol Cancer Ther       Date:  2020-01-15       Impact factor: 6.261

6.  KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Authors:  Yuen Yee Cheng; Casey M Wright; Michaela B Kirschner; Marissa Williams; Kadir H Sarun; Vladimir Sytnyk; Iryna Leshchynska; J James Edelman; Michael P Vallely; Brian C McCaughan; Sonja Klebe; Nico van Zandwijk; Ruby C Y Lin; Glen Reid
Journal:  Mol Cancer       Date:  2016-06-01       Impact factor: 27.401

7.  MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.

Authors:  Ruby C Y Lin; Michaela B Kirschner; Yuen Yee Cheng; Nico van Zandwijk; Glen Reid
Journal:  Genom Data       Date:  2016-06-20

Review 8.  MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.

Authors:  Jana Merhautova; Regina Demlova; Ondrej Slaby
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

Review 9.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 10.  microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges.

Authors:  Nadia Cherradi
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-20       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.